BrainStorm Cell Therapeutics Reaches Alignment With FDA On Chemistry, Manufacturing, And Control Aspects Of Phase 3b NurOwn Clinical Trial For Amyotrophic Lateral Sclerosis
Portfolio Pulse from Benzinga Newsdesk
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) has reached alignment with the FDA on the Chemistry, Manufacturing, and Controls (CMC) aspects of its Phase 3b clinical trial for NurOwn, an investigational therapy for amyotrophic lateral sclerosis (ALS).
June 26, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BrainStorm Cell Therapeutics has reached alignment with the FDA on the CMC aspects of its Phase 3b clinical trial for NurOwn, an investigational therapy for ALS. This is a positive regulatory development that could enhance investor confidence.
Reaching alignment with the FDA on CMC aspects is a significant regulatory milestone. It indicates progress in the clinical trial process, which could lead to positive sentiment among investors and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100